About sorafenib in castration-resistant prostate cancer
- PMID: 18689865
- DOI: 10.1093/annonc/mdn546
About sorafenib in castration-resistant prostate cancer
Comment on
-
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.Ann Oncol. 2008 Apr;19(4):746-51. doi: 10.1093/annonc/mdm554. Epub 2007 Dec 3. Ann Oncol. 2008. PMID: 18056648 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
